Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Plasma cell myeloma refractory

Recruiting

InvestigationalNo placebo

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Teclistamab

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Ovarian cancer

Recruiting

Registered drugNo placebo

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Ischaemic stroke

Recruiting

Registered drugNo placebo

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Tenecteplase

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

Norway

Participants:18–64 years · 65+ years
Substances:BLEXIMENIB

Contact Research Centre

Endometrial cancer+1

Recruiting

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Db-1303

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Daratumumab

Contact Research Centre

IgA nephropathy

Recruiting

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Norway

Participants:18–64 years · 65+ years

Contact Research Centre

Transitional cell carcinoma

Recruiting

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Endometrial cancer

Recruiting

Registered drugNo placebo

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you – page 2

128 trials match your criteria

Plasma cell myeloma refractory

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

Neuroendocrine carcinoma

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Fallopian tube cancer+2

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Ovarian cancer

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Ischaemic stroke

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Acute myeloid leukaemia

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Endometrial cancer+1

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Triple negative breast cancer

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Plasma cell myeloma

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

IgA nephropathy

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Transitional cell carcinoma

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Endometrial cancer

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.